Rapid responses to nilotinib in newly diagnosed early Ph+ CML

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

ORLANDO-In newly diagnosed, early chronic phase, Ph+ chronic myelogenous leukemia, nilotinib (Tasigna) quickly induced complete cytogenetic responses and was well tolerated, Jorge Cortes, MD, of M.D. Anderson Cancer Center, said at ASH 2007 (abstract 29).

ORLANDO-In newly diagnosed, early chronic phase, Ph+ chronic myelogenous leukemia, nilotinib (Tasigna) quickly induced complete cytogenetic responses and was well tolerated, Jorge Cortes, MD, of M.D. Anderson Cancer Center, said at ASH 2007 (abstract 29).

The trial included 35 newly diagnosed (6 months or less) adult patients with Ph+ CML in early chronic phase who had no prior therapy or less than a month of treatment with interferon-alfa or imatinib (Gleevec). Patients received 400 mg nilotinib twice daily, with dose reductions to 200 mg twice or once daily allowable. Seven patients had received prior imatinib for less than 1 month (patients with minimal prior therapy were eligible). Mean follow-up was 6.5 months.

All 33 evaluable patients had a complete hematologic response, and 30 of 31 (96%) with at least 3 months follow-up achieved CCyR. MMRs were reported in 14 of 32 (45%) and complete molecular responses (CMR) in 5 of 32 (16%). Within 3 months of therapy, 97% had a major cytogenetic response (MCR). In addition, MCRs were obtained in all 20 patients with 6 months of follow-up and in all 11 with 12 months.

At 3 months, BCR-ABL transcript levels were reduced by a median of 2-log and at 6 months by 3-log. By 6 months, at least 50% achieved MMR. CCyRs with nilotinib compared favorably with historic imatinib experience (see Figure).

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content